
RESOLUTIONS PASSED AT THE ANNUAL GENERAL MEETING HELD ON 29 SEPTEMBER 2026

Capitalised terms used herein, unless otherwise defined, shall have the definitions ascribed to them in the annual report of the Company for the financial year ended 31 May 2026 (“AR2026”) which was despatched to shareholders of HC Surgical Specialists Limited (the “Company”) on 14 September 2026.

The Board of Directors of the Company is pleased to announce that, pursuant to Rule 704(15) of the Singapore Exchange Securities Trading Limited (“SGX-ST”) Listing Manual Section B: Rules of Catalist (the “Catalist Rules”), all of the resolutions set out in the Notice of the Annual General Meeting (“AGM”) dated 14 September 2026 were duly passed by way of poll, at the AGM held on 29 September 2026.

(a) The results of the poll on the resolutions put to the vote at the AGM are as follows:

Resolution number and details		Total number of shares represented by votes for and against the relevant resolution	For		Against	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
Ordinary Business						
1	Re-election of Dr. Chia Kok Hoong as Director of the Company ⁽¹⁾	112,583,397	112,583,397	100	0	0.00
2	Re-election of Mr. Chong Weng Hoe as Director of the Company ⁽²⁾	112,583,397	112,583,397	100	0	0.00
3	Directors' Fees of S\$129,250/- for the financial year ended 31 May 2026	112,583,397	112,583,397	100	0	0.00
4	Declaration of final dividend (tax-exempt one-tier) of S\$0.0118 per ordinary share for the financial year ended 31 May 2026	112,583,397	112,583,397	100	0	0.00

Resolution number and details		Total number of shares represented by votes for and against the relevant resolution	For		Against	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
Ordinary Business						
5	Re-appointment of Messrs BDO LLP as auditors of the Company	112,583,397	112,583,397	100	0	0.00
Special Business						
6	Authority to issue ordinary shares	112,583,397	112,441,597	99.87	141,800	0.13
7	Proposed Renewal of the Share Buy-Back Mandate	48,594,417	48,572,617	99.96	21,800	0.04
8	Proposed Adoption of the 2026 HCSS Employee Share Option Scheme (“ 2026 HCSS ESOS ”)	13,612,577	13,590,777	99.84	21,800	0.16
9	Authority to offer and grant option(s) at a discount under the 2026 HCSS ESOS	13,612,577	13,470,777	98.96	141,800	1.04
10	Proposed Adoption of the 2026 HCSS Performance Share Plan (“ 2026 HCSS PSP ”)	13,612,577	13,590,777	99.84	21,800	0.16

Notes:

- (1) Dr. Chia Kok Hoong, who was re-elected as a Director under Resolution 1, remains as the Executive Director and Medical Director of the Company.
- (2) Mr. Chong Weng Hoe (“Mr Chong”), who was re-elected as a Director under Resolution 2, remains as the Non-Independent Non-Executive Director of the Company. Mr Chong will assume the role of a member of the Audit and Risk Management Committee, Remuneration Committee and Nominating Committee of the Company. Mr Chong is not considered independent for the purpose of Rule 704(7) of the Catalist Rules.

(b) Details of parties who abstained from voting are as follows:

<u>Resolution</u>	<u>Abstaining Party</u>	<u>Shareholding</u>
7	Dr. Heah Sieu Min	63,988,980
8, 9 and 10	Dr. Heah Sieu Min	63,988,980
	Dr. Chia Kok Hoong	34,753,440
	Mr. Chong Weng Hoe	167,600
	All other eligible participants of the 2026 HCSS ESOS and 2026 HCSS PSP	228,400

(c) Name of firm appointed as Scrutineer:

Entrust Advisory Pte. Ltd. was appointed as the scrutineer for the AGM.

By Order of the Board

Dr. Heah Sieu Min
Executive Director and Chief Executive Officer

Date: 29 September 2026

About HC Surgical Specialists Limited

HC Surgical Specialists Limited (the “Company”) was incorporated on 1 September 2015 in Singapore and listed on the Catalist of the Singapore Exchange Securities Trading Limited on 3 November 2016. The Company, its subsidiaries and associated company are a medical services group primarily engaged in the provision of endoscopic procedures, including gastroscopies and colonoscopies, and general surgery services with a focus on colorectal procedures across a network of 19 clinics located throughout Singapore.

This announcement has been reviewed by the Company’s sponsor, Novus Corporate Finance Pte. Ltd. (the “**Sponsor**”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “**Exchange**”) and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #04-02 Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.